The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Factors to consider when approaching R/R multiple myeloma
Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, explains the key components considered when approaching the treatment of relapsed/refractory (R/R) multiple myeloma, including patient characteristics, disease biology, and treatment toxicity. Dr El Hassadi highlights the importance of considering a patient’s prior exposure to therapies, and discusses the use of daratumumab, triplet therapy, and transplantation in this setting. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
